Q-omics provides the consensus-scored PATE4 profile across patient tissues and cancer cell-line models. PATE4 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in TGCT. Among the 18 cancer types available for tumor–normal comparison, PATE4 is differentially expressed in 9, with the highest sampling consensus in HNSC. Additionally, PATE4 RNA expression shows 12,640 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight TGCT, HNSC, and THYM as cancer lineages where PATE4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PATE4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PATE4 survival associations across molecular data types. PATE4 RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PATE4 RNA expression–survival associations across cancer types. High PATE4 expression shows unfavorable associations in TGCT, KIRP and CESC, but favorable associations in LAML, SCLC and GBM. The TGCT Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify TGCT as the clearest survival context for PATE4 RNA expression.
This table summarizes PATE4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for PATE4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PATE4 shows lower tumor expression in THCA and UCEC and higher tumor expression in HNSC, BRCA, CHOL and LUSC. The HNSC box plot shows higher PATE4 RNA expression in tumor versus normal tissue (log2 FC = +0.008, t-test p = .012).
This table shows molecular features associated with PATE4 in patient tissues and cancer cell lines. In patient samples, PATE4 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, PATE4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in OVARY and SKIN.
